Key facts
- It has raised $2.9M; the latest was Later Stage VC in Dec 2025.
- Notable investors include Johnson & Johnson Innovation - JLABS, Empower Investment, Shanghai Highpower Industrial, HiMed Fund, Joyin Incubator — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Xinguang Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Xinguang Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Xinguang Bio
Manufacturer of biopharmaceutical devices intended for therapeutic and diagnostic application purpose. The company uses enzymes to efficiently, rapidly, and selectively remove harmful molecules from blood, plasma, and dialysis effluents, enabling patients to have an alternative treatment for refractory metabolic diseases, cancer, and liver and kidney malfunction..
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2018
- Employees
- 3
- Ownership
- Privately Held (backing)
Xinguang Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Xinguang Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Xinguang Bio in its N-PORT filings yet. We sweep new filings monthly.